Summit Therapeutics (SMMT) EBITDA (2019 - 2024)
Summit Therapeutics (SMMT) posted EBITDA of -$65.6 million for Q4 2024, down 12.4% on a QoQ basis from -$58.4 million in Q3 2024, and down 81.2% year-over-year from -$349.1 million in Q1 2024.
Summit Therapeutics (SMMT) EBITDA (2019 - 2024) Analysis & Trends
Summit Therapeutics' EBITDA history runs 6 years deep, the most recent figure standing at -$65.6 million for Q4 2024.
- Quarterly EBITDA fell 81.2% year-over-year to -$65.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$226.0 million (up 62.93% YoY) and the FY2024 annual result came in at -$226.0 million, up 62.93% from the prior year.
- EBITDA was -$65.6 million for Q4 2024 at Summit Therapeutics, down from -$58.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$9.3 million in Q1 2020 and bottomed at -$537.2 million in Q1 2023.
- A 5-year average of -$52.4 million and a median of -$20.4 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA sank 2324.2% — and 2024, when it jumped 92.11%.
- Summit Therapeutics' EBITDA stood at -$11.6 million in 2020, then slumped by 125.4% to -$26.0 million in 2021, then grew by 22.07% to -$20.3 million in 2022, then slumped by 78.38% to -$36.2 million in 2023, then sank by 81.2% to -$65.6 million in 2024.
- Business Quant data shows SMMT's EBITDA at -$65.6 million in Q4 2024, -$58.4 million in Q3 2024, and -$59.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.61 Mn |
| Sep 30, 2024 | -58.38 Mn |
| Jun 30, 2024 | -59.62 Mn |
| Mar 31, 2024 | -42.39 Mn |
| Dec 31, 2023 | -36.21 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -537.15 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -22.16 Mn |
| Dec 31, 2021 | -26.05 Mn |
| Sep 30, 2021 | -19.49 Mn |
| Jun 30, 2021 | -23.73 Mn |
| Mar 31, 2021 | -16.92 Mn |
| Dec 31, 2020 | -11.56 Mn |
| Sep 30, 2020 | -16.94 Mn |
| Jun 30, 2020 | -15.36 Mn |
| Mar 31, 2020 | -9.34 Mn |